Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-19T09:29:09.707Z Has data issue: false hasContentIssue false
  • English
  • Français

Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics

Published online by Cambridge University Press:  01 January 2021

Ka Lum ,
Taimur Bhatti ,
Silas Holland ,
Mark Guthrie  and
Stephanie Sassman
Get access Rights & Permissions [Opens in a new window]

Extract

The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue S1: Incentives to Stimulate Research and Development of New Antibiotics: Detailed Assessments of Select Incentives and Models , Spring 2018 , pp. 66 - 74
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Joint Statement on Antibiotic Resistance from 25 National Health Organizations and the Centers for Disease Control and Prevention, available at <https://www.cddep.org/wp-content/uploads/2017/06/3._consensus_statement-1_8.pdf> (last visited March 25, 2018).+(last+visited+March+25,+2018).>Google Scholar
The Review on Antimicrobial Resistance: Chaired by O'Neil, Jim, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, May 2016; World Bank, Drug-Resistant Infections: A Threat to Our Economic Future (Discussion Draft), Washington, D.C., 2016.Google Scholar
DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” at 4, 2018, available at <http://www.imi.europa.eu/projects-results/project-factsheets/drive-ab> (March 25, 2018).+(March+25,+2018).>Google Scholar
Wellcome Trust, Four Diagnostic Strategies for Better-Targeted Antibiotic Use, available at <https://wellcome.ac.uk/sites/default/files/diagnostic-strategies-for-better-targeted-antibiotic-use-wellcome-jul15.pdf> (last visited March 25, 2018).+(last+visited+March+25,+2018).>Google Scholar
Raman, G., Avendano, E., Berger, S., and Menon, V., “Appropriate Initial Antibiotic Therapy in Hospitalized Patients with Gram-Negative Infections: Systematic Review and Meta-analysis,” BMC Infectious Diseases 15 (2015): 395; M. D. Zilberberg, A. F. Shorr, S. T. Micek, C. Vazquez-Guillamet, and M. H. Kollef, “Multi-drug Resistance, Inappropriate Initial Antibiotic Therapy and Mortality in Gram-Negative Severe Sepsis and Septic Shock: A Retrospective Cohort Study,” Critical Care 18 (2014): 596; P. Viale, M. Giannella, R. Lewis, E.M. Trecarichi, N. Petrosillo, and M. Tumbarello, “Predictors of Mortality in Multidrug-Resistant Klebsiella Pneumoniae Bloodstream Infections,” Expert Review of Anti-infective Therapy 11, no. 10 (2013): 1053-1063; A. F. Shorr, M. D. Zilberberg, S. T. Micek, and M. H. Kollef, “Predictors of Hospital Mortality among Septic ICU Patients with Acinetobacter spp. Bacteremia: A Cohort Study,” BMC Infectious Diseases 14 (2014): 572; T. P. Lodise Jr., N. Patel, A. Kwa, J. Graves, J. P. Furuno, E. Graffunder, B. Lomaestro, and J. C. McGregor, “Predictors of 30-Day Mortality among Patients with Pseudomonas Aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection,” Antimicrobial Agents Chemotherapy 51, no. 10 (2007): 3510-3515; J. Rello, “Importance of Appropriate Initial Antibiotic Therapy and De-escalation in the Treatment of Nosocomial Pneumonia,” European Respiratory Review 16 (2007): 33-39.Google Scholar
See supra note 5.Google Scholar
Garnacho-Montero, J., Escoresca-Ortega, A., and Fernández-Delgado, E., “Antibiotic de-Escalation in the ICU: How Is It Best Done?” Current Opinion in Infectious Diseases 28, no. 2 (2015): 193–198.Google Scholar
See Garnacho-Montero, supra note 7.Google Scholar
Id.Google Scholar
Koechlin, F., Konijn, P., Lorenzoni, L., and Schreyer, P., “Comparing Hospital and Health Prices and Volumes Internationally: Results of a Eurostat/OECD Project,” OECD Health Working Papers, no. 75 (2014): at 11; V. Paris, M. Devaux, and L. Wei, “Health Systems Institutional Characteristics: A Survey of 29 OECD Countries,” OECD Health Working Papers, no. 50 (2010): at 36.Google Scholar
Scheller-Kreinsen, D., Quentin, W., and Busse, R., “DRG-Based Hospital Payment Systems and Technological Innovation in 12 European Countries,” Value in Health 14 (2011): 1166–1172.CrossRefGoogle Scholar
Busse, R., Geissler, A., Quentin, W., and Wiley, M., eds., Diagnosis-Related Groups in Europe. Moving Towards Transparency, Efficiency and Quality in Hospitals (Berkshire, England: Open University Press, 2011).Google Scholar
See Scheller-Kreinsen, supra note 11; see Busse, supra note 12.Google Scholar
Schaffer, S. K., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterton, R., and Fischer, A., “Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions,” Office of Health Economics (May 2017), available at <https://www.ohe.org/system/files/private/publications/OHEAIMAssessingTheValueofNewAntibioticsMay2017.pdf> (last visited March 25, 2018); G. Daniel, M. McClellan, and G. Lavezzari, Tracking the Progress of Economic Incentives for Antimicrobial Drug Development in the U.S. and Across the Globe, Duke-Margolis Center for Health Policy (November 2016), available at <https://healthpolicy.duke.edu/sites/default/files/atoms/files/Antimicrobial%20Economic%20Incentives%20Landscape%20Analysisv2.pdf> (last visited March 25, 2018).+(last+visited+March+25,+2018);+G.+Daniel,+M.+McClellan,+and+G.+Lavezzari,+Tracking+the+Progress+of+Economic+Incentives+for+Antimicrobial+Drug+Development+in+the+U.S.+and+Across+the+Globe,+Duke-Margolis+Center+for+Health+Policy+(November+2016),+available+at++(last+visited+March+25,+2018).>Google Scholar
Boucher, H. W., Ambrose, P. G., Chambers, H. F., Ebright, R. H., Jezek, A., Murray, B. E., Newland, J. G., Ostrowsky, B., and Rex, J. H., on behalf of the Infectious Diseases Society of America, “White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs,” Journal of Infectious Diseases 216, no. 2 (2017): 228–236.CrossRefGoogle Scholar
Goff, D. A. and File, Jr., “The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections Review Article,” Infectious Disease Clinics of North America 30, no. 2 (2016): 539–551.CrossRefGoogle Scholar
Outterson, K., Powers, J. H., Daniel, G. W., and McClellan, M. B., “Repairing the Broken Market for Antibiotic Innovation,” Health Affairs 34, no. 2 (2015): 277–285; J. O'Neill, Securing New Drugs for Future Generations: The Pipeline for Antibiotics (2015), available at <http://amr-review.org/sites/default/files/SECURINGNEWDRUGSFORFUTUREGENERATIONSFINALWEB_0.pdf> (last visited March 25, 2018); Boston Consulting Group for the German Federal Ministry of Health, Breaking through the Wall (2017), available at <https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf> (last visited March 25, 2018); Infectious Diseases Society of America, IDSA Comments — CMS CY2015 PFS Proposed Rule (2014), available at <https://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Access_and_Reimbursement/2013/2015IPPScomments_Final(1).pdf> (last visited March 25, 2018).CrossRefGoogle Scholar
Årdal, C., Røttingen, J.-A., Opalska, A., Van Hengel, A. J., and Larsen, J., “Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance,” Clinical Infectious Diseases 65, no. 8 (2017): 1378–1382.Google Scholar
See Schaffer, supra note 14.Google Scholar
See Årdal, supra note 18.Google Scholar
Neumann, P. J., Chambers, J. D., Simon, F., and Meckley, L. M., “Risk-Sharing Arrangements That Link Payment for Drugs to Health Outcomes Are Proving Hard to Implement,” Health Affairs 30, no. 12 (2011): 2329–2337.Google Scholar
Norwegian Ministry of Health and Care Services, National Strategy against Antibiotic Resistance 2015–2020 (2015), available at <https://www.regjeringen.no/contentassets/5eaf66ac392143b3b2054aed90b85210/antibiotic-resistance-engelsk-lavopploslig-versjon-for-nett-10-09-15.pdf> (last visited March 25, 2018).+(last+visited+March+25,+2018).>Google Scholar
Public Health England, “Start Smart—Then Focus, Antimicrobial Stewardship Toolkit for English Hospitals,” 2015, available at <https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus> (last visited March 25, 2018).+(last+visited+March+25,+2018).>Google Scholar
Team, C, “Chennai Declaration: 5-Year Plan to Tackle the Challenge of Anti-microbial Resistance,” Indian Journal of Medical Microbiology 32, no. 32 (2014): 221–228.Google Scholar